

**Managing common infections NICE guideline**  
**Clostridioides difficile infection: antimicrobial prescribing**  
**(Meeting 4)**  
**Minutes**

**Date:** 29/09/20

**Location:** Virtual

**Committee members present:**

Tessa Lewis – Chair (TL)	Present for items 1 - 8
Yarni Finney (YF)	Present for part of item 5
Alastair Hay (AH)	Present for items 1 - 8
Ian Hill-Smith (IH)	Present for items 1 - 8
Philip Howard (PH)	Present for items 1 - 8
Marisa Lanzman (ML)	Present for items 1 - 8
Paddy McMaster (PM)	Present for items 1 - 8
John Morris (JM)	Present for items 1 - 8
Mitul Patel (MP)	Present for items 1 - 8
Carole Pitkeathley (CP)	Present for items 1 - 8
Avril Tucker (AT)	Present for items 1 - 8
Caroline Ward (CW)	Present for items 1 - 8
Nirouz Zarroug (NZ)	Present for items 1 - 8

**Expert witness:**

Mark Wilcox	Present for item 5
-------------	--------------------

**In attendance (NICE):**

Helen Barnett (HB)	Present for items 1 - 8
Sara Buckner (SB)	Present for items 1 - 8
Alex Curwen (AC)	Present for items 1 - 8
Rupert Franklin (RF)	Present for items 1 - 8
Ruth Garnett (RG)	Present for items 1 - 8
James Jagroo (JJ)	Present for items 1 - 8
Greg Moran (GM)	Present for items 1 - 8
Louise Picton (LP)	Present for items 1 - 8
Joshua Pink (JP)	Present for items 1 - 8
Ian Pye (IP)	Present for items 1 - 8
Adam Storrow (AS)	Present for items 1 - 8
Jonathan Underhill (JU)	Present for items 1 - 8

**In attendance (YHEC):**

Tom Bromilow (TB)

Present for items 1 - 8

Hayden Holmes (HH)

Present for items 1 - 8

**Apologies:**

Stephanie Dancer, Susan Hopkins, Amelia Joseph

**1. Welcome, introductions and apologies**

The chair welcomed the committee members and attendees to clostridioides difficile infection meeting 4 of the public health advisory committee D (managing common infections committee). The committee members and attendees introduced themselves.

The chair informed the committee that apologies had been received as noted above.

The chair outlined the objectives of the meeting, which included:

- Economic modelling for Clostridioides difficile infection
- Discussion of evidence and draft recommendations for Clostridioides difficile infection: antimicrobial prescribing

**2. Declaration of interests**

The chair asked the committee to declare any new or relevant interests.

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest</b>
Philip Howard	Consultant Antimicrobial Pharmacist, Leeds Teaching Hospitals NHS Trust	Astellas funded research grant to undertake study for this paper: Goldenberg, S. D, Brown, S., Edwards, L., Gnanarajah, D., Howard, P et al. (2016). "The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations." Eur J Clin Microbiol Infect Dis 35(2): 251-259. Paper won Prix Galien Prize for Real World Evidence.
Philip Howard	Consultant Antimicrobial Pharmacist, Leeds Teaching Hospitals NHS Trust	2014 Talks on fidaxomicin real experience at 3 Astellas sponsored events.

Alastair Hay	Part time salaried GP at The Concord Medical Centre, Bristol & Professor of Primary Care, University of Bristol.	Co-authoring 'Rational use of antibiotics': BMJ Learning modules.
Marisa Lanzman	Senior Pharmacist – Microbiology/ITU Royal Free London NHS Foundation Trust	Co-author for a chapter on 'Sepsis in Adults' in 'Drugs in Use' 6th Edition. Remuneration = £125.
Mitul Patel	Consultant Microbiologist and Clinical Lead (Microbiology), Birmingham Children's Hospital NHS Trust. Consultant Microbiologist, Birmingham Women's Hospital NHS Trust	Paediatric antibiotic stewardship programmes in the UK's regional children's hospitals. S. Vergnano, A. Bamford,..+M. Patel,..S. Patel. The Journal of Hospital Infections. August 2020. vol:105 (4); 736-740
Mitul Patel	Consultant Microbiologist and Clinical Lead (Microbiology), Birmingham Children's Hospital NHS Trust. Consultant Microbiologist, Birmingham Women's Hospital NHS Trust	Clinical and cost-effectiveness of antimicrobial stewardship programmes. Pooja Shivananda Siddhi, Mitul Patel Journal of the Academy of Clinical Microbiologists, 2019 Volume: 21 Issue: 2 Page: 60-65
Nirouz Zarroug	Clinical Specialist Dietitian Clatterbridge Cancer Centre Liverpool	MRes: The effects of prebiotic consumption on adults with gastrointestinal infection and gastrointestinal inflammation: A Systematic Review. Scholarship Sponsored by the Royal Liverpool University Hospital

The chair and a senior member of the NICE Development team (NDT) noted that the interests declared did not prevent the attendees from participating in the meeting at the chair's discretion.

### 3. Update on current topics and process

JU updated the committee on the changes at NICE in response to the COVID-19 pandemic and the necessary reassessment of priorities.

#### **4. Beinortas NMA recap**

10:20 JM joined the meeting and had no new declarations of interest.

JJ briefly presented the evidence considered at the previous committee meeting in December 2019 and informed the committee of a newly identified RCT. He then presented the findings of the Beinortas 2018 network meta-analysis.

#### **5. Economic modelling for Clostridioides difficile infection**

10:45 MW joined the meeting. AC briefed the committee on his role as an expert witness and reminded them of his most notable conflicts of interest. MW had nothing further to add.

HH presented the economic evaluation for clostridioides difficile infection (CDI) and the committee discussed the data.

11:20 YF joined the meeting and declared a new interest; NICE Public Involvement Panel membership. The chair and a senior member of the NDT noted that the interest declared did not prevent YF from participating in the meeting.

The committee continued to discuss the economic evaluation data.

13:30 TL invited any last comments from MW and thanked him before he left the meeting.

The committee discussed draft recommendations.

14:00 TL asked YF if she had anything further to contribute and thanked her before she left the meeting.

#### **6. Recap of clinical evidence for Clostridioides difficile infection: antimicrobial prescribing**

JJ presented a summary of the evidence reviewed so far for CDI.

#### **7. Discussion of evidence and draft recommendations for Clostridioides difficile infection: antimicrobial prescribing**

The guideline was shared on screen and RG explained the changes made since the last committee meeting. SB made notes on the guideline.

The committee discussed the antibiotic table and agreed draft recommendations.

15:45 CP left the meeting.

The committee discussed research recommendations.

**8. Any other business**

SB informed the committee that she was leaving the MCI team to go to the COVID team for an 18-month secondment.

The meeting closed at 16:00.